Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline Buys Back 1.3 Million Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 06:28pm CEST

GlaxoSmithKline PLC (>> GlaxoSmithKline plc) said Friday it has purchased 1,300,000 ordinary shares to be held in treasury.

MAIN FACTS:

-Highest price paid: 1455 pence per share.

-Lowest price paid: 1425 pence per share.

-Shares at 1610 GMT down 1%, at 1427 pence, valuing the company at GBP72 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc, GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
12:16p GLAXOSMITHKLINE : GSK gets approvals for `bubble boy` syndrome gene therapy in U..
10:10a GLAXOSMITHKLINE : Shingrix approved in the US for prevention of shingles in adul..
07:11a ASTRAZENECA : Pharma giants top list of R&D big spenders
10/23 GLAXOSMITHKLINE : OGM ratifies cash dividends
10/23 European stocks hold firm as banks, Spanish shares fall
10/23 NICE APPROVES GLAXOSMITHKLINE PLC (A : GSK) Gene Therapy Strimvelis
10/23 GLAXOSMITHKLINE : GSK's Shingrix Receives US FDA Approval
10/21 GLAXOSMITHKLINE : New GlaxoSmithKline shingles vaccine gets FDA approval
10/21 GLAXOSMITHKLINE : Shingrix approved in the US for prevention of shingles in adul..
10/20GLAXOSMITHKLINE PLC : quaterly earnings release
More news
News from SeekingAlpha
10/23 BIG BIOTECH IN THE CRISPR GAME : Novartis And Vertex Lead The Pack
10/23 GlaxoSmithKline Lands Big Win For Shingles Vaccine
10/23 Agenus up 11% premarket on FDA OK of Glaxo's shingle vaccine
10/20 CytoDyn Dresses HIV Patients In CCR5 Halloween 'Mask'
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
Financials ( GBP)
Sales 2017 30 145 M
EBIT 2017 8 481 M
Net income 2017 4 019 M
Debt 2017 14 126 M
Yield 2017 5,26%
P/E ratio 2017 19,84
P/E ratio 2018 15,94
EV / Sales 2017 2,95x
EV / Sales 2018 2,87x
Capitalization 74 739 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,1  GBP
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-2.72%98 757
JOHNSON & JOHNSON23.60%385 476
NOVARTIS13.97%226 424
PFIZER12.13%216 767
ROCHE HOLDING LTD.0.77%206 094
MERCK AND COMPANY7.69%172 914